

**Day 1: October 2 (Thursday) 2025**

Room 2 “Orion” 5<sup>th</sup> Floor

**14:20-15:20 Late Breaking Oral Session**

---

**LBO-1** #10242

**Histologic Improvement and Sustained Benefit Across Hepatic and Metabolic Biomarkers with Pegzofermin Therapy: Results from a 48-week Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2b trial (ENLIVEN)**

Dr. Rohit Loomba (USA)

**LBO-2** #10243

**Insights from Phase 2 Study Results for Survodutide in People with MASH Fibrosis F1-F3**

Dr. Ahmad Alhussein (Germany)

**LBO-3** #10239

**TMBIM5 Attenuates High-fat-mediated Liver Injury by Activating Fundc1-related Mitophagy and Suppressing Drp1-related Fission**

Dr. Qi Shen (China)

**LBO-4** #10241

**The Mechanism of TMBIM5 in Ameliorating Alcohol-related Liver Disease by Regulating Mitochondrial Dynamics**

Dr. Qi Shen (China)

**LBO-5** #10246

**Using a Human Liver-on-a-chip Model to Study Alcohol-associated Liver Disease by Targeting LSEC and ALDH2**

Dr. Takashi Tsuchiya (USA)

**Day 1: October 2 (Thursday) 2025**

Poster Session “Matsu”, “Subaru” or Foyer 5<sup>th</sup> Floor

**17:40-18:10 Late Breaking Poster Session**

---

**LBP-1** #10236

**Drug Induced Liver Injury Secondary to Anabolic Steroid Use in a Young Filipino Male: A Case Report and Therapeutic Challenge**

Dr. Kaye Bernice T. Siao (Philippines)

**LBP-2** #10237

**Acute Liver Failure Due to Anti-Tuberculosis Drug-Induced Liver Injury: A Case Report from Indonesia**

Dr. Fahmi Fauzi Sugandi (Indonesia)

**LBP-3** #10238

**Zonal Differences in Hepatocellular Mitochondrial Depolarization, Mitophagy, and Respiration after Acute Ethanol**

Dr. Kenji Takemoto (USA)

**LBP-4** #10240

**Once-monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis with F2/F3 Fibrosis: Results from A 24 Week, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial**

Dr. Matthew Bryant (USA)

**LBP-5** #10244

**Therapeutic Evaluation of Resmetirom and Semaglutide in the STAM Mouse Model: Bridging Surrogate and Clinical Outcomes**

Dr. Taishi Hashiguchi (Japan)